Corifact (1000-1600 IU)
Biological
CSL Behring
Total Payments
$42,055
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $42,055 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $42,055 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Research F XIII function during clot formation, structure and stability for in vitro and in vivo studies in mice | CSL Behring | $42,055 | 0 |
Top Doctors Receiving Payments for Corifact (1000-1600 IU)
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chapel Hill, NC | $42,055 | 1 |
Ad
Manufacturing Companies
- CSL Behring $42,055
Product Information
- Type Biological
- Total Payments $42,055
- Total Doctors 0
- Transactions 1
About Corifact (1000-1600 IU)
Corifact (1000-1600 IU) is a biological associated with $42,055 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2017. In 2017, $42,055 was paid across 1 transactions to 0 doctors.
The most common payment nature for Corifact (1000-1600 IU) is "Unspecified" ($42,055, 100.0% of total).
Corifact (1000-1600 IU) is associated with 1 research study, including "Research F XIII function during clot formation, structure and stability for in vitro and in vivo studies in mice" ($42,055).